1923836-86-5

Basic information

• Product Name: ethyl 2-(4-(6-fluoroquinolin-4-yl)cyclohex-3-enyl)acetate
• Synonyms: ethyl 2-(4-(6-fluoroquinolin-4-yl)cyclohex-3-enyl)acetate
• CAS NO: 1923836-86-5
• Molecular Formula: C19H20FNO2
• Molecular Weight: 313.3660032
• EINECS: -0
• Mol File: 1923836-86-5.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 2-(4-(6-fluoroquinolin-4-yl)cyclohex-3-enyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-(4-(6-fluoroquinolin-4-yl)cyclohex-3-enyl)acetate(1923836-86-5)
• EPA Substance Registry System: ethyl 2-(4-(6-fluoroquinolin-4-yl)cyclohex-3-enyl)acetate(1923836-86-5)

Safety Data

• Hazardous Substances Data: 1923836-86-5(Hazardous Substances Data)

Upstream product

• 51656-91-8 ethyl 1,4-dioxaspiro[4,5]dec-8-ylideneacetate 
• 62141-26-8 ethyl 1,4-dioxaspiro[4.5]dec-8-ylacetate 
• 1166829-72-6 ethyl 2-(4-(((trifluoromethyl)sulfonyl)oxy)cyclohex-3-en-1-yl)acetate 
• 661463-17-8 4-bromine-6-fluoroquinoline 
• 1166829-70-4 ethyl 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)cyclohex-3-en-1-yl)acetate 
• 391-77-5 4-Chloro-6-fluoroquinoline 
• 58012-34-3 ethyl 4-oxocyclohexaneacetate 
• 4746-97-8 cyclohexanedione monoethylene ketal 

Relevant articles and documents

Discovery of Imidazopyridines as Potent Inhibitors of Indoleamine 2,3-Dioxygenase 1 for Cancer Immunotherapy

Indoleamine 2,3-dioxygenase 1 (IDO1) has been identified as a target for small-molecule immunotherapy for the treatment of a variety of cancers including renal cell carcinoma and metastatic melanoma. This work focuses on the identification of IDO1 inhibitors containing replacements or isosteres for the amide found in BMS-986205, an amide-containing, IDO1-selective inhibitor currently in phase III clinical trials. Detailed subsequently are efforts to identify a structurally differentiated IDO1 inhibitor via the pursuit of a variety of heterocyclic isosteres, leading to the discovery of highly potent, imidazopyridine-containing IDO1 inhibitors.

PENTAFLUOROSULFANYL-SUBSTITUTED AMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND MEDICAL APPLICATION THEREOF

The present invention relates to a novel pentafluorosulfanyl-substituted amide compound that regulates or inhibits indoleamine 2,3-dioxygenase (IDO) activity, its preparation method and its application in medicine. Specifically, the present invention relates to a compound represented by general formula (I) and pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or pharmaceutically acceptable salt thereof, application of the compound or pharmaceutically acceptable salt thereof for treating and/or preventing related disorders mediated by IDO, especially tumors, and a method for preparing the compound or pharmaceutically acceptable salt thereof. The present invention also relates to the preparation of the compound or pharmaceutically acceptable salt thereof or a pharmaceutical composition containing the compound or pharmaceutically acceptable salt thereof for the treatment and/or prevention of IDO-mediated related disorders, especially for use in tumor treatment. The substituents in the general formula (I) are the same as descripted in the specification.

AMIDE-SUBSTITUTED IMIDAZO COMPOUNDS AS SELECTIVE INHIBITORS OF INDOLEAMINE 2, 3-DIOXYGENASES

Disclosed herein are amide-substituted imidazo compounds and pharmaceutical compositions comprising at least one such novel benzoimidazoles, processes for the preparation thereof, and the method for using the same in therapy. In particular, disclosed herein are certain amide-substituted imidazo compounds that are useful for inhibiting indoleamine 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.